ArticleWomen's health reports (New Rochelle, N.Y.)2025
An Investigation on Modifiable and Nonmodifiable Estrogen Exposure and Gray Matter Volume in Healthy Older Women.
Article in Women's health reports (New Rochelle, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: It is projected that the global population of adults above age 60 years will surpass 2 billion by 2050. Age-related cognitive decline represents a prevalent issue and research has demonstrated that women are at greater risk than men. Changes in cognitive function with age are influenced by many factors and may include lifetime exposure to estrogen and the transition to menopause. While the exact relationship between estrogen and the aging brain is unclear, the hormonal changes in menopause have been associated with a decline in gray matter volume. However, some studies have demonstrated that the use of hormone therapy may mitigate some of the effects of cognitive decline. Methods: The current study used magnetic resonance imaging and voxel-based morphometry to examine the relationship between gray matter volume and endogenous lifetime estrogen exposure ( Results: Results demonstrated no significant correlations between whole brain gray matter volume and lifetime estrogen exposure. There were no significant differences between groups based on hormone therapy use. However, there was a nonsignificant relationship that suggested that women who did not use hormone therapy had greater gray matter volume than those who did use it. Discussion: As the aging population continues to grow globally, it is essential to better understand the variables that influence trajectories of aging; especially for women, who are particularly at risk for age-related cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.